Local innovative drug companies join forces to actively explore clinical value!

【Pharmaceutical Network Industry News】Recently, Fosun Pharma and Kofipin Pharmaceutical announced a cooperation in which the two parties will jointly develop and independently develop the first potassium competitive acid blocker (P-CAB) "Caprasan hydrochloride", which includes all available indications for oral preparations and ordinary injections of Keprasen hydrochloride, and the two sides will cooperate
globally.

Keprasen hydrochloride is suitable for the treatment of duodenal ulcer, reflux esophagitis and Helicobacter pylori infection, etc.
, and the drug has many obvious advantages
such as fast onset of action and stable acid suppression.

In China, the drug has completed two Phase III clinical studies of duodenal ulcer and gastroesophageal reflux, and submitted a marketing application for 2 indications to the State Food and Drug Administration in September 2021, and is currently undergoing review and approval
.

In addition, Keprasen hydrochloride injection has been approved by the State Food and Drug Administration in May 2022 to carry out Phase I clinical studies
in China.

In the United States, the drug has completed 1 phase I clinical study
.

According to the license agreement, in China (excluding Hong Kong, Macao and Taiwan, the same below), as the marketing authorization holder of the cooperative products, Fosun Pharma Industry enjoys exclusive commercialization rights, including marketing and distribution
.

Outside of China, Fosun Pharma, as the holder of the marketing authorization for the cooperative products, enjoys exclusive product rights, including but not limited to clinical research, registration, commercialization, sub-licensing, etc
.

As the first self-developed potassium competitive acid blocker (P-CAB) in China, if the drug is successfully marketed, it is expected to bring new treatment options
to the majority of patients.

Fosun Pharma said that it will make full use of Fosun Pharma's innovation capabilities, international advantages and commercialization capabilities accumulated over the years to strive to improve drug accessibility so that patients can benefit from this domestic innovative drug
as soon as possible.

In recent years, the cooperation between Chinese pharmaceutical companies has become more and more frequent, and from the cooperation between generic drug companies in the past to the cooperation
between innovative drug companies.

For example, Hengrui Pharmaceutical cooperates frequently with domestic pharmaceutical companies, and the cooperation objects involve Wanchun Pharmaceutical and Cornerstone Pharmaceutical
.

Among them, in November 2021, Hengrui Pharmaceutical and CStone Pharmaceutical reached a strategic cooperation agreement of more than 1 billion yuan that has attracted much attention in the industry, introducing the latter's anti-CTLA-4 monoclonal antibody CS1002, and Hengrui Pharmaceutical will obtain the exclusive rights
to develop, register, produce and commercialize CS1002 in Greater China.

In addition, Yifan Pharmaceutical's subsidiary Yiyi Biologics and Chia Tai Tianqing's subsidiaries Nanjing Shunxin, Jichuan Pharmaceutical and Tianjing Biologics and other local pharmaceutical companies have also carried out cooperation to complement the advantages of both sides through "marriage", better promote research and development, accelerate the commercialization process, and benefit more patients
faster.

In the industry's view, the choice of local innovative drug companies to cooperate with local pharmaceutical companies in terms of products is actually a recognition
of their clinical value itself.

The phenomenon of joint commercialization, especially joint development, between domestic pharmaceutical companies is also closely
related to the country's active encouragement of innovation.

In November 2021, CDE's "Clinical Value-oriented Guidelines for the Clinical Development of Antitumor Drugs" was officially implemented, advocating that clinical value itself is oriented and patients are the core
.

Under this new policy, the industry believes that domestic pharmaceutical companies will pay more attention to the true innovation of drugs and actively explore clinical value
.

Disclaimer: Under no circumstances does the information herein or the opinions expressed in this article constitute investment advice
to any person.